Pyrilutamide

Chemical compound From Wikipedia, the free encyclopedia

Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) which is under development for the treatment of androgenic alopecia (pattern hair loss) and acne.[1][2][3] The drug is being developed by Suzhou Kintor Pharmaceuticals.[1] As of February 2025, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne.[1] The drug was also under development for the treatment of diabetic foot ulcers, but development for this indication was discontinued.[1]

Other namesKX-826; KX826
Routes of
administrationTopical[1]
Drug classNonsteroidal antiandrogen; Androgen receptor antagonist
ATC code
  • None
Quick facts Clinical data, Other names ...
Pyrilutamide
Clinical data
Other namesKX-826; KX826
Routes of
administration		Topical[1]
Drug classNonsteroidal antiandrogen; Androgen receptor antagonist
ATC code
  • None
Identifiers
  • 4-(3-(4-cyano-2-fluoro-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC21H15F5N4O2S
Molar mass482.43 g·mol−1
3D model (JSmol)
  • CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=C(F)C(=C(C=C1)C#N)C(F)(F)F
  • InChI=1S/C21H15F5N4O2S/c1-20(2)18(32)29(14-7-4-10(9-27)15(16(14)23)21(24,25)26)19(33)30(20)11-5-6-12(13(22)8-11)17(31)28-3/h4-8H,1-3H3,(H,28,31)
  • Key:CGRMNGGGSWLDDC-UHFFFAOYSA-N
Close

Pharmacology

Pharmacodynamics

Pyrilutamide is a selective and high-affinity silent antagonist of the androgen receptor (AR). It has an affinity (IC50Tooltip half-maximal inhibitory concentration) of 0.28 nM, relative to 3.1 nM in the case of bicalutamide.[3]

See also

References

Related Articles

Wikiwand AI